THERE IS THE POTENTIAL FOR CROSS-SENSITIVITY TO ACETYLSALICYLIC ACID, PHENYLACETIC ACID DERIVATIVES, AND OTHER NSAID AGENTS. THEREFORE, CAUTION SHOULD BE USED WHEN TREATING INDIVIDUALS WHO HAVE PREVIOUSLY EXHIBITED SENSITIVITIES TO THESE DRUGS.
NEPAFENAC AT CONCENTRATIONS UP TO 300 NG/ML DID NOT INHIBIT THE IN VITRO METABOLISM OF 6 SPECIFIC MARKER SUBSTRATES OF CYTOCHROME P450 (CYP) ISOZYMES (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, AND CYP3A4). THEREFORE, DRUG-DRUG INTERACTIONS INVOLVING CYP MEDIATED METABOLISM OF CONCOMITANTLY ADMINISTERED DRUGS ARE UNLIKELY. DRUG-DRUG INTERACTIONS MEDIATED BY PROTEIN BINDING ARE ALSO UNLIKELY.